Steve Elms - Jun 12, 2025 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role
Director
Signature
/s/ Steve Elms, by Michael A. Goldstein as Attorney-in-fact
Stock symbol
ADMA
Transactions as of
Jun 12, 2025
Transactions value $
-$7,688,571
Form type
4
Date filed
6/16/2025, 09:00 PM
Previous filing
Jun 9, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ELMS STEVE Director C/O AISLING CAPITAL MANAGEMENT LP, 489 FIFTH AVENUE, 10TH FLOOR, NEW YORK /s/ Steve Elms, by Michael A. Goldstein as Attorney-in-fact 2025-06-16 0001250195

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADMA Stock Option (Right to Buy) Options Exercise $0 -9K -100% $0.00 0 Jun 13, 2025 Common Stock 9K $5.96 Direct F7
transaction ADMA Stock Option (Right to Buy) Options Exercise $0 -10K -100% $0.00 0 Jun 13, 2025 Common Stock 10K $5.00 Direct F7
transaction ADMA Stock Option (Right to Buy) Options Exercise $0 -53.8K -100% $0.00 0 Jun 13, 2025 Common Stock 53.8K $3.66 Direct F7
transaction ADMA Stock Option (Right to Buy) Options Exercise $0 -17.5K -100% $0.00 0 Jun 13, 2025 Common Stock 17.5K $4.91 Direct F7
transaction ADMA Stock Option (Right to Buy) Options Exercise $0 -30K -100% $0.00 0 Jun 13, 2025 Common Stock 30K $3.89 Direct F8
transaction ADMA Stock Option (Right to Buy) Options Exercise $0 -15K -100% $0.00 0 Jun 13, 2025 Common Stock 15K $2.92 Direct F8
transaction ADMA Stock Option (Right to Buy) Options Exercise $0 -55K -100% $0.00 0 Jun 13, 2025 Common Stock 55K $2.35 Direct F8
transaction ADMA Stock Option (Right to Buy) Options Exercise $0 -53.2K -100% $0.00 0 Jun 13, 2025 Common Stock 53.2K $1.67 Direct F8
transaction ADMA Stock Option (Right to Buy) Options Exercise $0 -51.6K -100% $0.00 0 Jun 13, 2025 Common Stock 51.6K $3.35 Direct F8
transaction ADMA Stock Option (Right to Buy) Options Exercise $0 -37.5K -100% $0.00 0 Jun 13, 2025 Common Stock 37.5K $5.40 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.37 to $22.17, inclusive. The reporting person undertakes to provide to ADMA Biologics, Inc. (the "Issuer"), any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (5).
F2 These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10-year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest therein.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.39, inclusive.
F4 Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the reporting person's continued service as of such vesting date and (ii) 271,190 shares of common stock owned by the reporting person.
F5 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.02 to $20.40, inclusive.
F6 Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the reporting person's continued service as of such vesting date and (ii) 76,441 shares of common stock owned by the reporting person.
F7 These options vested in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant.
F8 These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.